• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在欧洲消除 HPV 相关癌症:追求可能。

Eliminating HPV-caused cancers in Europe: Achieving the possible.

机构信息

HPV Action Network, European Cancer Organisation, Brussels, Belgium.

HPV Action Network, European Cancer Organisation, Brussels, Belgium.

出版信息

J Cancer Policy. 2021 Jun;28:100280. doi: 10.1016/j.jcpo.2021.100280. Epub 2021 Mar 18.

DOI:10.1016/j.jcpo.2021.100280
PMID:35559909
Abstract

The 690,000 cases of cancer caused worldwide each year by HPV (human papillomavirus) are among the easiest of all cancers to prevent. However, the actions so far taken in terms of both policy and practice by health systems in many European states have neither matched the scale of the problem nor seized the opportunities for disease prevention potentially offered by vaccination and screening. Treatments for HPV-caused cancers are also inequitably provided across the region and widespread misinformation about HPV undermines efforts to improve public health. The European Cancer Organisation's HPV Action Network has made the case for action for the elimination of all the cancers caused by HPV through gender-neutral vaccination, effective cervical cancer screening, better quality treatments, and public and professional education across Europe. The World Health Organisation's new global strategy for the elimination of cervical cancer (launched in November 2020), together with Europe's Beating Cancer Plan (February 2021), together provide a major opportunity to tackle decisively all the cancers caused by HPV. The Beating Cancer Plan, which was significantly influenced by evidence provided by the HPV Action Network, commits to supporting EU member states' efforts to extend routine vaccination of girls and boys and to creating a new EU-supported Cancer Screening Scheme to help Member States ensure that 90% of the EU population who qualify for cervical cancer screening are offered it by 2025. The goal of HPV cancer elimination is now both possible and achievable. The challenge is to ensure implementation and delivery by EU member states and more widely across the European region.

摘要

每年全球有 69 万例由 HPV(人乳头瘤病毒)引起的癌症病例,这是所有癌症中最容易预防的癌症之一。然而,许多欧洲国家的卫生系统在政策和实践方面采取的行动既没有与问题的规模相匹配,也没有抓住疫苗接种和筛查可能带来的疾病预防机会。该地区各地对 HPV 引起的癌症的治疗也不平等,并且对 HPV 的广泛误解破坏了改善公共卫生的努力。欧洲癌症组织的 HPV 行动网络呼吁采取行动,通过对所有性别进行中性疫苗接种、有效的宫颈癌筛查、更好的治疗质量以及在整个欧洲进行公共和专业教育,消除所有由 HPV 引起的癌症。世界卫生组织新的全球消除宫颈癌战略(2020 年 11 月启动),以及欧洲的战胜癌症计划(2021 年 2 月),共同为果断解决所有由 HPV 引起的癌症提供了一个重大机会。《战胜癌症计划》在很大程度上受到 HPV 行动网络提供的证据的影响,该计划承诺支持欧盟成员国努力扩大女孩和男孩的常规疫苗接种,并创建一个新的欧盟支持的癌症筛查计划,以帮助成员国确保到 2025 年,有资格接受宫颈癌筛查的欧盟 90%的人口都能接受筛查。消除 HPV 癌症的目标现在是既可能又可实现的。挑战在于确保欧盟成员国和更广泛的欧洲地区的实施和交付。

相似文献

1
Eliminating HPV-caused cancers in Europe: Achieving the possible.在欧洲消除 HPV 相关癌症:追求可能。
J Cancer Policy. 2021 Jun;28:100280. doi: 10.1016/j.jcpo.2021.100280. Epub 2021 Mar 18.
2
HPV-Related Cancers: A Growing Threat to U.S. Military Health and Readiness.HPV 相关癌症:美国军事健康与战备面临的日益严重的威胁。
Mil Med. 2022 May 3;187(5-6):149-154. doi: 10.1093/milmed/usab443.
3
Human papillomavirus vaccination in the European Union/European Economic Area and globally: a moral dilemma.人乳头瘤病毒疫苗接种在欧盟/欧洲经济区和全球范围内:一个道德困境。
Euro Surveill. 2021 Dec;26(50). doi: 10.2807/1560-7917.ES.2021.26.50.2001659.
4
Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.人乳头瘤病毒在俄罗斯联邦、前苏联西方国家、高加索地区和中亚的流行情况和型别分布、宫颈癌筛查实践以及疫苗接种实施现状。
Vaccine. 2013 Dec 31;31 Suppl 7:H46-58. doi: 10.1016/j.vaccine.2013.06.043.
5
Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.人乳头瘤病毒流行率和型别分布、在中欧和东欧的宫颈癌筛查做法以及当前疫苗接种实施状况。
Vaccine. 2013 Dec 31;31 Suppl 7:H59-70. doi: 10.1016/j.vaccine.2013.03.029.
6
Comprehensive control of human papillomavirus infections and related diseases.人乳头瘤病毒感染及相关疾病的综合防控。
Vaccine. 2013 Dec 29;31 Suppl 5:F1-31. doi: 10.1016/j.vaccine.2013.10.001.
7
Combining cervical cancer screening for mothers with schoolgirl vaccination during human papillomavirus (HPV) vaccine implementation in South Africa: results from the VACCS1 and VACCS2 trials.在南非实施人乳头瘤病毒(HPV)疫苗接种期间,将母亲的宫颈癌筛查与女学生疫苗接种相结合:VACCS1和VACCS2试验结果
Int J Gynecol Cancer. 2022 May 3;32(5):592-598. doi: 10.1136/ijgc-2021-003079.
8
From cervical cancer elimination to eradication of vaccine-type human papillomavirus: Feasibility, public health strategies and cost-effectiveness.从消除宫颈癌到根除疫苗型人乳头瘤病毒:可行性、公共卫生策略及成本效益
Prev Med. 2021 Mar;144:106354. doi: 10.1016/j.ypmed.2020.106354. Epub 2020 Dec 10.
9
Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans.欧洲基于 HPV 的宫颈癌初筛:实施现状、挑战与未来计划。
Clin Microbiol Infect. 2020 May;26(5):579-583. doi: 10.1016/j.cmi.2019.09.006. Epub 2019 Sep 17.
10
[Vaccination against human papillomavirus].[人乳头瘤病毒疫苗接种]
Internist (Berl). 2021 Aug;62(8):816-826. doi: 10.1007/s00108-021-01102-0. Epub 2021 Jul 14.

引用本文的文献

1
The Role of Scientific Research in Human Papillomavirus Vaccine Discussions on Twitter: Social Network Analysis.《在 Twitter 上关于人乳头瘤病毒疫苗讨论中的科学研究作用:社会网络分析》。
JMIR Infodemiology. 2024 May 9;4:e50551. doi: 10.2196/50551.
2
DNA methylation as a triage marker for colposcopy referral in HPV-based cervical cancer screening: a systematic review and meta-analysis.基于 HPV 的宫颈癌筛查中 DNA 甲基化作为阴道镜转诊的分流标志物:系统评价和荟萃分析。
Clin Epigenetics. 2023 Aug 2;15(1):125. doi: 10.1186/s13148-023-01537-2.
3
The Association of Health Literacy with Intention to Vaccinate and Vaccination Status: A Systematic Review.
健康素养与接种意愿及疫苗接种状况的关联:一项系统综述
Vaccines (Basel). 2022 Oct 29;10(11):1832. doi: 10.3390/vaccines10111832.